Auto Amazon Links: No products found. Blocked by captcha.
Last week, it was revealed that Northern Ireland was participating in a clinical trial related to gender identity services, a matter examined in a review conducted by Dr Hilary Cass. However, this involvement has since been suspended by Health Minister Mike Nesbitt. First Minister Michelle O’Neill expressed disappointment over the decision, suggesting that Nesbitt should have first consulted the executive before acting. She criticized the move, describing it as influenced by intra-unionist rivalry and emphasizing that it showed a lack of support for the trans community. O’Neill also distanced herself from the decision, calling for more sensitivity in handling such matters.
Nesbitt defended his choice, stating that it was made independently and appropriately. In a statement to The News Letter, he explained that due to an ongoing judicial review of the UK government’s clinical trial involving puberty blockers, Northern Ireland’s participation would remain paused until the legal issues were resolved. He also made clear that any future resumption of involvement would be discussed with executive colleagues. Additionally, Nesbitt is scheduled to face questions from assembly members regarding how he arrived at this decision. UUP leader Jon Burrows stood by the health minister’s action, affirming his support.
Baroness Hilary Cass, a consultant in paediatric disability and former president of the Royal College of Paediatrics and Child Health, was appointed by Nesbitt to review Northern Ireland’s gender identity services. Her investigation included discussions with service staff and users, and she recommended that Northern Ireland align its clinical practices with those in England. The services, which benefit from referrals through Child and Adolescent Mental Health Services (CAMHS), offer early mental health support when needed. However, some CAMHS staff expressed frustration over delays experienced by children waiting to access the “Knowing Our Identity” service, which assists children, young people, and their families with gender-related issues. Baroness Cass also highlighted the need for improved research into the characteristics and outcomes of young people seeking treatment and advocated for a smoother transition from youth to adult services through a Lifespan care model.
The Rainbow Project condemned the suspension of Northern Ireland’s involvement in the trial, describing it as a politically motivated decision rather than one based on evidence. Alexa Moore from the group remarked that while the executive had previously cited evidence to justify banning puberty blockers, this latest move clearly stemmed from political considerations. The trial in question aimed to assess the safety and efficacy of puberty blockers, which are drugs designed to delay or prevent puberty, by monitoring their effects on the physical, social, and emotional well-being of participants. Nesbitt expressed appreciation for Baroness Cass and her team’s work during their visit to Northern Ireland and expressed hope that the new Lifespan Gender Service would meet the standards outlined in the 2024 review, reinforcing the investment in additional psychological and psychiatric support as the appropriate course of action
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.